Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)
Bristol-Myers Squibb Company PFD CONV 2 operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Princeton, DE, US. The stock last traded at $400.00, down 57.46% on the session, giving a market capitalisation of $814.59B. On trailing twelve-month figures it carries a trailing P/E of 6.74, a net margin of 15.0%. Its beta of 0.27 implies it has historically moved less than the broad market.
Bristol-Myers Squibb is a pharmaceutical company dedicated to the research, development, and commercialization of treatments for a wide array of medical conditions. Its primary therapeutic domains include cardiovascular health, oncology, and immunological disorders. A significant strategic emphasis for the firm is immuno-oncology, an area where it has established itself as a leading innovator in developing new drugs. The company generates approximately 70% of its total revenue from the United States, indicating a considerably higher reliance on the American market compared to many of its industry counterparts.
Bristol-Myers Squibb Company PFD CONV 2 is most often compared with the following Healthcare names: